HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ophthalmic antibiotic use and multidrug-resistant staphylococcus epidermidis: a controlled, longitudinal study.

AbstractPURPOSE:
To analyze the emergence of multidrug-resistant Staphylococcus epidermidis after repeated conjunctival exposure to topical macrolide or fluoroquinolone antibiotics.
DESIGN:
Prospective, controlled, longitudinal study with 1-year follow-up.
PARTICIPANTS:
Forty-eight eyes of 24 patients undergoing serial unilateral intravitreal (IVT) injections for choroidal neovascularization.
METHODS:
Subjects received 4 consecutive monthly unilateral IVT injections and then were treated as needed. Each subject was assigned randomly to 1 of 4 antibiotics (azithromycin 1%, gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%) and used only their assigned antibiotic after each injection. Conjunctival culture specimens of the treated and untreated fellow eye (control) were obtained at baseline and after each injection. All bacterial isolates were tested for antibiotic susceptibility to 16 different antibiotics using the Kirby-Bauer disc diffusion technique.
MAIN OUTCOME MEASURES:
Antibiotic susceptibility patterns and multidrug resistance of S. epidermidis.
RESULTS:
After 4 consecutive treatments, a total of 58 isolates of S. epidermidis each were isolated from control and treated eyes. Resistance to 3 or more antibiotics was present in 69% of S. epidermidis isolated from control eyes compared with 90% from treated eyes (P<0.02). A total of 46 and 38 isolates of S. epidermidis were cultured from control and treated eyes, respectively, from the fifth until the final injection. Resistance to 5 or more antibiotics was present in 48% of control eyes compared with 71% of treated eyes (P<0.05). In a significant number of fluoroquinolone-treated eyes, S. epidermidis developed resistance to third-generation (P<0.01) and fourth-generation (P<0.01) fluoroquinolones compared with control eyes. In addition, these organisms developed resistance to trimethoprim/sulfamethoxazole (P<0.01), gentamicin (P<0.03), and clindamycin (P<0.05). Similarly, a significant number of azithromycin-treated eyes developed S. epidermidis resistant to macrolides (P<0.01) compared with control eyes and also developed increased resistance to trimethoprim/sulfamethoxazole (P<0.02) and doxycycline (P<0.01).
CONCLUSIONS:
Conjunctival S. epidermidis repeatedly exposed to fluoroquinolone or azithromycin antibiotics rapidly develop resistance. Coresistance to other antibiotics also was observed.
FINANCIAL DISCLOSURE(S):
Proprietary or commercial disclosure may be found after the references.
AuthorsSarita B Dave, Hassanain S Toma, Stephen J Kim
JournalOphthalmology (Ophthalmology) Vol. 118 Issue 10 Pg. 2035-40 (Oct 2011) ISSN: 1549-4713 [Electronic] United States
PMID21856006 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Azithromycin
  • Ofloxacin
  • Gatifloxacin
  • Moxifloxacin
Topics
  • Adult
  • Anti-Bacterial Agents (administration & dosage, therapeutic use)
  • Aza Compounds (administration & dosage, therapeutic use)
  • Azithromycin (administration & dosage, therapeutic use)
  • Choroidal Neovascularization (drug therapy)
  • Conjunctiva (microbiology)
  • Drug Resistance, Multiple, Bacterial
  • Fluoroquinolones (administration & dosage, therapeutic use)
  • Follow-Up Studies
  • Gatifloxacin
  • Humans
  • Intravitreal Injections
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Ofloxacin (administration & dosage, therapeutic use)
  • Prospective Studies
  • Quinolines (administration & dosage, therapeutic use)
  • Staphylococcus epidermidis (drug effects, isolation & purification)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: